SERIES A-1 COMMON STOCK PURCHASE WARRANT NEUBASE THERAPEUTICS, INC.NeuBase Therapeutics, Inc. • October 18th, 2023 • Pharmaceutical preparations • New York
THIS SERIES A-1 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Armistice Capital Master Fund Ltd. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Closing (as defined below) (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on January 2, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from NeuBase Therapeutics, Inc., a Delaware corporation (the “Company” as further defined below), up to [______] shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to that certain Exchange Agreement, dated as of October 17, 2023, by and between the Company and Holder (as may be amend
exchange AgreementExchange Agreement • October 18th, 2023 • NeuBase Therapeutics, Inc. • Pharmaceutical preparations • New York
This Exchange Agreement (this “Agreement”) is dated as of October 17, 2023, by and between NeuBase Therapeutics, Inc. or any Successor Entity thereto (together, the “Company”) and Armistice Capital Master Fund Ltd. (the “Warrant Holder”). Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Securities Purchase Agreements (as defined below) and the New Warrant (as defined below).
